Soft Tissue Sarcoma Market to Undergo Significant Growth with a CAGR of 8.43% through 2028
Increasing prevalence of
various types of soft tissue sarcomas and intensive R&D activities on drugs
to drive global soft tissue sarcoma market
According
to TechSci Research report, “Global
Soft
Tissue Sarcoma Market By Treatment Type (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, Others), By End Users (Hospitals, Homecare, Specialty Centers, Others), By Region, Forecast & Opportunities, 2028”, the global soft tissue sarcoma market is poised to undergo
a robust growth during the forecast period as the world is witnessing
increasing cases and prevalence of various types of soft tissue sarcomas. Global Soft Tissue Sarcoma Market has valued at USD 1.33 Billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 8.43% through 2028. Moreover,
growing awareness among people and increasing research & development
activities to find the advanced drugs and therapies such as targeted and
biological therapies to cure the disease are some key factors propelling the
growth of soft tissue sarcoma market. Further, increase in approval for
manufacture of generic drugs are expected to fuel the market growth until 2028.
Additionally, rising funding and grants by governments for research is providing
a major boost to the global soft tissue sarcoma market. Apart from that, rise
in quality patient care and patent expiry of branded drugs are other factors
driving the growth this market. There are around 50 different types of soft
tissue sarcoma and there is a growing need to find a suitable treatment for the
ailment. With more manufacturers entering the market, the global soft tissue
sarcoma market is anticipated to witness significant growth in the coming
years.
However, the market also faces some challenges. High
cost and side effects associated with cancer treatment are restraining the
growth of global soft tissue sarcoma market. Also, stringent government
regulations and shortage of doxorubicin, which is one of the major drugs used
in chemotherapy, might act as barriers to the overall growth of this market.
Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on "Global Soft Tissue Sarcoma Market"
The global
soft tissue sarcoma market is segmented based on treatment, disease type, end
user and region. Based on treatment, the market is segmented into targeted
therapy, chemotherapy, anti-angiogenesis drug and radiation therapy. Here, the chemotherapy
segment accounted for largest market share until 2018 and is expected to
dominate the market through 2028 as the treatment uses a combination of various
anti-cancer drugs and has high success rate compared to other cancer treatments.
Based on end user, the global soft tissue sarcoma market is categorized into hospitals,
oncology center, long term care center. As the shortage of oncology centers,
especially in developing nations is a major issue, therefore the market is
currently being dominated by hospitals. However, with increasing expenditure on
healthcare and rise in number of oncology centers, the oncology center segment
is expected to undergo fastest growth during the forecast period.
Major players operating in the global soft
tissue sarcoma market include GlaxoSmithKline plc, Eli Lilly and Company,
Pfizer, Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche AG, Johnson &
Johnson Services, Inc., Teva Pharmaceutical Industries Ltd, Celgene
Corporation, BioHorizons, Zimmer Holdings, RTI Biologics, MiMedx, Atrium
Medical and Integra LifeSciences. The companies are focusing on new product
launches and research & development activities to bring more effective
treatments and drugs for soft tissue sarcoma.
Download Free Sample Report
Customers
can also request for 10% free customization on this report.
“North
America is emerging as the biggest market for soft tissue sarcoma as the region
has a large population suffering from chronic diseases such as cancer. The
advanced healthcare facilities and rising awareness about soft tissue sarcoma
are making the region one of the most favorable markets for the manufacturers.
The region is expected to be followed by Europe and Asia-Pacific, which are
also witnessing rising cases of soft tissue sarcoma”, said Mr. Karan Chechi,
Research Director of TechSci Research, a research based global management
consulting firm.
“Soft Tissue Sarcoma Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented By Treatment Type (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, Others), By End Users (Hospitals, Homecare, Specialty Centers, Others), By Region and Competition,” has
evaluated the future growth potential of global soft tissue sarcoma market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges and opportunities in global soft tissue sarcoma market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com